Pharmacopeia Identifies Additional Lead Compounds

Pharmacopeia has identified two new lead compounds for advancement in its alliance with GlaxoSmithKline (GSK) through its collaboration with the Center of Excellence for External Drug Discovery.

One compound forms the basis of a program focused on identifying a treatment for respiratory disease. The other compound is the second from a program in inflammatory pain.

Pharmacopeia said it will receive milestone payments of $1 million from GSK.